Pliant Therapeutics, Inc. (Nasdaq: PLRX) today announced that following a prespecified data review and recommendation by the ...
Pliant Therapeutics shares were halted in early morning trading after falling 25% to $2.57, after the company said it is discontinuing a phase 2b trial for bexotegrast in patients with idiopathic ...
Pliant Therapeutics discontinued its BEACON-IPF trial for bexotegrast due to safety concerns but observed early efficacy. The ...
SOUTH SAN FRANCISCO - Pliant Therapeutics, Inc. (NASDAQ: PLRX) reported fourth quarter earnings that beat analyst estimates, sending shares up 6.5% in after-hours trading. The cli ...
Pliant Therapeutics shares dropped 52% to $1.64, after the company said it was discontinuing a phase 2b trial for bexotegrast in patients with idiopathic pulmonary fibrosis. The stock hit its 52-week ...
NEW YORK CITY, NY / ACCESS Newswire / February 26, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential ...
Pliant Therapeutics (NASDAQ:PLRX – Get Free Report) is anticipated to issue its quarterly earnings data before the market ...
https://www.tipranks.com/news/the-fly/travere-therapeutics-price-target-raised-to-30-from-24-at-td-cowen JPMorgan downgraded Pliant Therapeutics (PLRX) to Neutral ...
Fintel on MSN21d
JP Morgan Downgrades Pliant Therapeutics (PLRX)Fintel reports that on February 10, 2025, JP Morgan downgraded their outlook for Pliant Therapeutics (NasdaqGS:PLRX) from Overweight to Neutral. Analyst Price Forecast Suggests 1,212.38% Upside As of ...
A clinical study testing a Pliant Therapeutics drug once considered a promising prospect for treating a fatal lung disorder is now on pause at the recommendation of independent outside observers.
Piper Sandler lowered the firm’s price target on Pliant Therapeutics (PLRX) to $17 from $40 and keeps an Overweight rating on the ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback